First LEA assay launched

LEA2 MPS Panel

Our first LEA2 (Lysosomal Enzyme Activity) assay has now been started and with it several mucopolysaccharidoses (MPS) can be diagnosed from one single Dried Blood Spot within a few days.

Various forms of MPS
With our LEA2 assay, it is possible to multiplex the diagnostics for MPS I (Hurler syndrome), MPS II (Hunter syndrome), MPS IIIB (Sanphilippo syndrome B), MPS IVa (Morquio A syndrome), MPS VI (Maroteaux Lamy syndrome) and MPS VII (Sly syndrome).

Fast and easy
No time-wasting stepwise diagnostics is needed any more, instead of weeks the reports are available within a few days. Additionally, genetic confirmatory testing using the power of Next-Generation Sequencing is available from the same Dried Blood Spot.

LEA2 CLN2

We also offer a new enzymatic test for CLN2 (late infantile neuronal ceroid lipofuscinosis type 2) disease, an ultra-rare and rapidly progressing pediatric brain disorder and one of the most common forms of neuronal ceroid lipofuscinosis, a group of inherited disorders collectively known as Batten disease.

Furthermore we provide a new confirmatory genetic test for the detection of mutations on the tripeptidyl peptidase 1 (TPP1) gene from the same Dried Blood Spot.

Show all Biotech & Pharma News
«
»